0001628280-24-015457.txt : 20240409 0001628280-24-015457.hdr.sgml : 20240409 20240409162013 ACCESSION NUMBER: 0001628280-24-015457 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240408 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240409 DATE AS OF CHANGE: 20240409 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Beauty Health Co CENTRAL INDEX KEY: 0001818093 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 851908962 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39565 FILM NUMBER: 24832970 BUSINESS ADDRESS: STREET 1: 2165 SPRING STREET CITY: LONG BEACH STATE: CA ZIP: 90806 BUSINESS PHONE: 800-603-4996 MAIL ADDRESS: STREET 1: 2165 SPRING STREET CITY: LONG BEACH STATE: CA ZIP: 90806 FORMER COMPANY: FORMER CONFORMED NAME: Vesper Healthcare Acquisition Corp. DATE OF NAME CHANGE: 20200714 8-K 1 skin-20240408.htm 8-K skin-20240408
FALSE0001818093Nasdaq00018180932024-04-082024-04-080001818093us-gaap:CommonStockMember2024-04-082024-04-08

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549  
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 8, 2024
 
The Beauty Health Company
(Exact name of registrant as specified in its charter)  
 
Delaware 001-39565 85-1908962
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
2165 Spring Street
Long Beach, CA
(Address of principal executive offices)

90806
(Zip Code)
(800) 603-4996
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Class A Common Stock, par value $0.0001 per share SKIN 
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐  
 


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Chief Operating Officer Departure

On April 8, 2024, The Beauty Health Company (the "Company") and Brad Hauser mutually agreed to terminate Mr. Hauser’s employment as Chief Operating Officer of the Company without cause, effective as of April 9, 2024. Mr. Hauser will remain with the Company in an advisory role until no later than June 30, 2024. Mr. Hauser’s separation is not a result of any disagreement with the Company on any matter relating to the Company’s financial reporting, operations, policies or practices.

The Company intends to file a separate, subsequent Current Report on Form 8-K within four business days after the Company and Mr. Hauser enter into a definitive separation agreement with respect to Mr. Hauser’s separation as Chief Operating Officer of the Company.





SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated: April 9, 2024The Beauty Health Company
By:/s/ Michael Monahan
Name:Michael Monahan
Title:Chief Financial Officer

 EX-101.SCH 2 skin-20240408.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 skin-20240408_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 4 skin-20240408_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Information [Line Items] Entity Information [Line Items] Document Period End Date Document Period End Date Equity Component [Domain] Equity Component [Domain] Class A Common Stock, par value $0.0001 per share Common Stock [Member] Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Equity Components [Axis] Equity Components [Axis] Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Document Type Document Type Amendment Flag Amendment Flag Entity File Number Entity File Number Entities [Table] Entities [Table] Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 skin-20240408_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
Apr. 08, 2024
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Apr. 08, 2024
Entity Registrant Name The Beauty Health Company
Entity Incorporation, State or Country Code DE
Entity File Number 001-39565
Entity Tax Identification Number 85-1908962
Entity Address, Address Line One 2165 Spring Street
Entity Address, City or Town Long Beach
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90806
City Area Code 800
Local Phone Number 603-4996
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001818093
Class A Common Stock, par value $0.0001 per share  
Entity Information [Line Items]  
Title of 12(b) Security Class A Common Stock, par value $0.0001 per share
Trading Symbol SKIN
Security Exchange Name NASDAQ
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 2 22 1 false 1 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://beautyhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName - skin-20240408.htm 4 skin-20240408.htm skin-20240408.xsd skin-20240408_def.xml skin-20240408_lab.xml skin-20240408_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "skin-20240408.htm": { "nsprefix": "skin", "nsuri": "http://beautyhealth.com/20240408", "dts": { "inline": { "local": [ "skin-20240408.htm" ] }, "schema": { "local": [ "skin-20240408.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "skin-20240408_def.xml" ] }, "labelLink": { "local": [ "skin-20240408_lab.xml" ] }, "presentationLink": { "local": [ "skin-20240408_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 2, "entityCount": 1, "segmentCount": 1, "elementCount": 28, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://beautyhealth.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skin-20240408.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skin-20240408.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Class\u00a0A Common Stock, par value $0.0001 per share", "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitiesTable", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationLineItems", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001628280-24-015457-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-015457-xbrl.zip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end XML 18 skin-20240408_htm.xml IDEA: XBRL DOCUMENT 0001818093 2024-04-08 2024-04-08 0001818093 us-gaap:CommonStockMember 2024-04-08 2024-04-08 false 0001818093 NASDAQ 8-K 2024-04-08 The Beauty Health Company DE 001-39565 85-1908962 2165 Spring Street Long Beach CA 90806 800 603-4996 false false false false Class A Common Stock, par value $0.0001 per share SKIN NASDAQ false